Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis
Stem Cells Translational Medicine · 2026
DOI: 10.1093/stcltm/szag083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2026. Verfasst von Violaine K Harris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tisch Multiple Sclerosis Research Center of New York, New York, NY 10019, United States. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Neural Stem Cells, Multiple Sclerosis. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Multiple Sclerosis Society and the Damial Foundation.
Abstract (Originalsprache)
Mesenchymal stem cell-neural progenitors (MSC-NP) are a bone marrow mesenchymal stem cell–derived population of cells with trophic and immunomodulatory properties with therapeutic potential in multiple sclerosis (MS). Early phase clinical trials have investigated the safety and efficacy of intrathecal administration of autologous MSC-NPs in people with progressive MS. To better understand the biological response to MSC-NP treatment, we analyzed cerebrospinal fluid (CSF) biomarkers in 2 separate cohorts of trial subjects with secondary progressive or primary progressive MS from both a phase 2 trial (n = 50) and an expanded access trial (n = 43) who received repeated administrations of autologous MSC-NPs. Candidate biomarkers identified through proteomic screening were validated in both cohorts, revealing a panel of 4 biomarkers (CCL2, C-C motif chemokine ligand-2; MMP9, matrix metalloproteinase-9; SCF, stem cell factor/c-kit ligand; and CHIT1, chitotriosidase-1) that were significantly changed in CSF but not serum following treatment. Other MS biomarkers neurofilament light and glial fibrillary acidic protein were unchanged following treatment but correlated with age, and both age and Expanded Disability Status Scale (EDSS), respectively. The specific biomarker changes observed following MSC-NP injections suggest distinct biological effects following MSC-NP treatment. These biomarkers help define the pharmacodynamic response to MSC-NP treatment as well as guide the design of future clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tisch Multiple Sclerosis Research Center of New York, New York, NY 10019, United States.
ORCID-Profile: Violaine K Harris, Saud A Sadiq
Förderung
- National Multiple Sclerosis Society and the Damial Foundation
Zitieren
APA
Harris, V. K., Jiang, A., Ricciarini, S., Jagid, N., McCormick, M., Kizilbash, C., & Sadiq, S. A. (2026). Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szag083
Vancouver
Harris VK, Jiang A, Ricciarini S, Jagid N, McCormick M, Kizilbash C, et al. Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Translational Medicine. 2026. doi:10.1093/stcltm/szag083
BibTeX
@article{Harris2026,
author = {Harris, Violaine K and Jiang, Andrea and Ricciarini, Sofia and Jagid, Nikki and McCormick, Maureen and Kizilbash, Cara and Sadiq, Saud A},
title = {Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis},
journal = {Stem Cells Translational Medicine},
year = {2026},
doi = {10.1093/stcltm/szag083}
}
EUVIMED